CA3181123A1 - Method for removing crustacean ectoparasites from farmed salmonid fish using water-soluble tetrapyrrole compounds and light - Google Patents
Method for removing crustacean ectoparasites from farmed salmonid fish using water-soluble tetrapyrrole compounds and light Download PDFInfo
- Publication number
- CA3181123A1 CA3181123A1 CA3181123A CA3181123A CA3181123A1 CA 3181123 A1 CA3181123 A1 CA 3181123A1 CA 3181123 A CA3181123 A CA 3181123A CA 3181123 A CA3181123 A CA 3181123A CA 3181123 A1 CA3181123 A1 CA 3181123A1
- Authority
- CA
- Canada
- Prior art keywords
- water
- soluble
- tetrapyrrole
- light
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 115
- 238000000034 method Methods 0.000 title claims abstract description 44
- 241001507086 salmonid fish Species 0.000 title claims abstract description 19
- 241000238424 Crustacea Species 0.000 title claims abstract description 15
- 244000078703 ectoparasite Species 0.000 title description 4
- 241000972773 Aulopiformes Species 0.000 claims abstract description 73
- 235000019515 salmon Nutrition 0.000 claims abstract description 73
- 241001674048 Phthiraptera Species 0.000 claims abstract description 67
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 208000015181 infectious disease Diseases 0.000 claims abstract description 12
- 229940099898 chlorophyllin Drugs 0.000 claims abstract description 10
- 235000019805 chlorophyllin Nutrition 0.000 claims abstract description 10
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 10
- 241001247234 Lepeophtheirus salmonis Species 0.000 claims abstract description 9
- 208000030852 Parasitic disease Diseases 0.000 claims abstract description 9
- 230000036281 parasite infection Effects 0.000 claims abstract description 9
- 241001611011 Caligus Species 0.000 claims abstract description 6
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims description 36
- 229920000858 Cyclodextrin Polymers 0.000 claims description 20
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 18
- 150000004032 porphyrins Chemical class 0.000 claims description 12
- 150000004036 bacteriochlorins Chemical class 0.000 claims description 4
- 150000004035 chlorins Chemical class 0.000 claims description 4
- 238000011282 treatment Methods 0.000 abstract description 47
- 241001611004 Caligus rogercresseyi Species 0.000 abstract description 5
- 239000003814 drug Substances 0.000 description 39
- 241000251468 Actinopterygii Species 0.000 description 38
- 235000019688 fish Nutrition 0.000 description 37
- 229940079593 drug Drugs 0.000 description 36
- 241000277263 Salmo Species 0.000 description 25
- 239000013535 sea water Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000002253 acid Substances 0.000 description 21
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 18
- 229910052802 copper Inorganic materials 0.000 description 18
- 239000010949 copper Substances 0.000 description 18
- 239000004570 mortar (masonry) Substances 0.000 description 17
- -1 tungsten halogen Chemical class 0.000 description 13
- 239000003504 photosensitizing agent Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229940088679 drug related substance Drugs 0.000 description 9
- 238000002428 photodynamic therapy Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000009360 aquaculture Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000654 additive Substances 0.000 description 6
- 244000144974 aquaculture Species 0.000 description 6
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 6
- 229940092714 benzenesulfonic acid Drugs 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 241000277275 Oncorhynchus mykiss Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000009313 farming Methods 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000002563 ionic surfactant Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 241000277289 Salmo salar Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 3
- 229960000907 methylthioninium chloride Drugs 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000009372 pisciculture Methods 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- PVPBHKCSQBLDEW-ZQOBQRRWSA-N (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol 4-hydroxybutane-1-sulfonic acid Chemical compound OCCCCS(O)(=O)=O.OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O PVPBHKCSQBLDEW-ZQOBQRRWSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000005892 Deltamethrin Substances 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- VEMKTZHHVJILDY-UXHICEINSA-N bioresmethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UXHICEINSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229960002483 decamethrin Drugs 0.000 description 2
- OWZREIFADZCYQD-NSHGMRRFSA-N deltamethrin Chemical compound CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 OWZREIFADZCYQD-NSHGMRRFSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-DYCDLGHISA-N deuterium hydrogen oxide Chemical compound [2H]O XLYOFNOQVPJJNP-DYCDLGHISA-N 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- JZRYQZJSTWVBBD-UHFFFAOYSA-N pentaporphyrin i Chemical compound N1C(C=C2NC(=CC3=NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JZRYQZJSTWVBBD-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NTGBUUXKGAZMSE-UHFFFAOYSA-N phenyl n-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(NC(=O)OC=3C=CC=CC=3)=CC=2)CC1 NTGBUUXKGAZMSE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 1
- 241000517745 Acartia Species 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 241000607620 Aliivibrio fischeri Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000790794 Argulus Species 0.000 description 1
- 102000005469 Chitin Synthase Human genes 0.000 description 1
- 108700040089 Chitin synthases Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000239250 Copepoda Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241001262815 Dactylogyrus Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000011811 Ichthyobodo Species 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 241001247233 Lepeophtheirus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- VQXSOUPNOZTNAI-UHFFFAOYSA-N Pyrethrin I Natural products CC(=CC1CC1C(=O)OC2CC(=O)C(=C2C)CC=C/C=C)C VQXSOUPNOZTNAI-UHFFFAOYSA-N 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241000219315 Spinacia Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 241001500087 Trichodina Species 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- VNKBTWQZTQIWDV-UHFFFAOYSA-N azamethiphos Chemical compound C1=C(Cl)C=C2OC(=O)N(CSP(=O)(OC)OC)C2=N1 VNKBTWQZTQIWDV-UHFFFAOYSA-N 0.000 description 1
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- FMASHOOOLPDQTK-UHFFFAOYSA-L disodium;4-(4-sulfonatobutoxy)butane-1-sulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCCCOCCCCS([O-])(=O)=O FMASHOOOLPDQTK-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- AKZFRMNXBLFDNN-UHFFFAOYSA-K meso-tetrakis(n-methyl-4-pyridyl)porphine tetrakis(p-toluenesulfonate) Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1.C1=C[N+](C)=CC=C1C(C=1C=CC(N=1)=C(C=1C=C[N+](C)=CC=1)C1=CC=C(N1)C(C=1C=C[N+](C)=CC=1)=C1C=CC(N1)=C1C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 AKZFRMNXBLFDNN-UHFFFAOYSA-K 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- HYJYGLGUBUDSLJ-UHFFFAOYSA-N pyrethrin Natural products CCC(=O)OC1CC(=C)C2CC3OC3(C)C2C2OC(=O)C(=C)C12 HYJYGLGUBUDSLJ-UHFFFAOYSA-N 0.000 description 1
- VJFUPGQZSXIULQ-XIGJTORUSA-N pyrethrin II Chemical compound CC1(C)[C@H](/C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 VJFUPGQZSXIULQ-XIGJTORUSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical group OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/10—Culture of aquatic animals of fish
- A01K61/13—Prevention or treatment of fish diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K63/00—Receptacles for live fish, e.g. aquaria; Terraria
- A01K63/04—Arrangements for treating water specially adapted to receptacles for live fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
- A01N59/20—Copper
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P7/00—Arthropodicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dentistry (AREA)
- Public Health (AREA)
- Agronomy & Crop Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Meat, Egg Or Seafood Products (AREA)
Abstract
Composition in the form of an aqueous solution comprising a chemical compound for use in a method of therapy using artificial light for an external crustacean parasite infection in salmonid fish, said external crustacean parasite infection comprises an infection of salmon lice, Lepeophtheirus salmonis, Caligus rogercresseyi and Caligus spp. Said chemical compound is a water-soluble tetrapyrrole compound or a pharma-ceutical acceptable derivative thereof, with the proviso that the water-soluble tetrapyrrole is not chlorophyllin. Said water-soluble tetrapyrrole compound is adminis-tered in a bath treatment of the salmonid fish in need of such treatment, and the salmon lice is illuminated by artificial light.
Description
METHOD FOR REMOVING CRUSTACEAN ECTOPARASITES FROM FARMED SALMONID FISH
USING WATER-SOLUBLE TETRAPYRROLE COMPOUNDS AND LIGHT
Field of the invention The invention relates to a new method for removing or killing of ectoparasites from farmed fish. More particularly, the invention relates to removing or killing crustacean ectoparasites from farmed fish. The fish may be a salnnonid fish, such as Atlantic salmon (SaImo salar L.) or rainbow trout (Oncorhynchus mykiss). The crustacean ec-toparasite may be salmon lice (Lepeophtheirus salmonis, Caligus rogercresseyi, Ca-ligus spp.). Even more particularly the invention relates to a method comprising treatment means where light from an artificial light source is used in combination with at least one chemical compound at toxicologically acceptable concentrations for fish, in particular salmonid fish. The method relates to the use of a combination of certain water-soluble tetrapyrrole compounds and light. In particular the invention relates to a composition in the form of an aqueous solution comprising the water-soluble tetrapyrrole compound or a pharmaceutical derivative thereof.
Background Aquaculture, also referred to as aquafarming, is the farming of aqueous organism.
Aquaculture involves cultivating fresh water and saltwater populations under con-trolled conditions and is in contrast to commercial harvesting or fishing where the or-ganisnns are naturally present. The farmed organisms can typically be fish, crusta-ceans, mollusks, aquatic plants, and algae. The aquaculture farms can be in the form of tanks (closed or semi closed), fishponds, ocean cages or nets.
Diseases, especially infectious diseases, are a problem in aquaculture. Within fish aq-uaculture, especially salmon farming, there has been a development of prophylactic therapy in the form of vaccines and development of treatment of disease in the form of various drugs. However, salmon lice infection remains a main problem regarding salmon farming.
USING WATER-SOLUBLE TETRAPYRROLE COMPOUNDS AND LIGHT
Field of the invention The invention relates to a new method for removing or killing of ectoparasites from farmed fish. More particularly, the invention relates to removing or killing crustacean ectoparasites from farmed fish. The fish may be a salnnonid fish, such as Atlantic salmon (SaImo salar L.) or rainbow trout (Oncorhynchus mykiss). The crustacean ec-toparasite may be salmon lice (Lepeophtheirus salmonis, Caligus rogercresseyi, Ca-ligus spp.). Even more particularly the invention relates to a method comprising treatment means where light from an artificial light source is used in combination with at least one chemical compound at toxicologically acceptable concentrations for fish, in particular salmonid fish. The method relates to the use of a combination of certain water-soluble tetrapyrrole compounds and light. In particular the invention relates to a composition in the form of an aqueous solution comprising the water-soluble tetrapyrrole compound or a pharmaceutical derivative thereof.
Background Aquaculture, also referred to as aquafarming, is the farming of aqueous organism.
Aquaculture involves cultivating fresh water and saltwater populations under con-trolled conditions and is in contrast to commercial harvesting or fishing where the or-ganisnns are naturally present. The farmed organisms can typically be fish, crusta-ceans, mollusks, aquatic plants, and algae. The aquaculture farms can be in the form of tanks (closed or semi closed), fishponds, ocean cages or nets.
Diseases, especially infectious diseases, are a problem in aquaculture. Within fish aq-uaculture, especially salmon farming, there has been a development of prophylactic therapy in the form of vaccines and development of treatment of disease in the form of various drugs. However, salmon lice infection remains a main problem regarding salmon farming.
2 Relevant prior art publications and their relevant content Currently several non-medicinal approaches are used to reduce the number of infected fish in the fish farm or to remove lice from infected fish. Several drugs are also cur-rently used to combat salmon lice infections in fish farming. The regulatory approved drug substances include organophosphates, pyrethroids and hydrogen peroxide.
Azannethiphos is an organophosphatase inhibitor of acetylcholinesterase. Aza-methiphos is the active substance in the commercial product Azasure.
Deltamethrin is a pyrethrin that interferes with the nerve membrane function in salmon lice resulting in paralysis and death. Deltamethrin is the active drug substance in the commercial io product ALPHA MAX. Hydrogen peroxide has for many years been used to combat salmon lice infections in fish including salmon. The mechanism of action is probably related to an oxidative effect on lice components and the formation of oxygen emboli within the salmon lice.
Development of drug resistance is a general problem with farming of fish including salmon, and currently the development of resistance is known for all drug substances used in fish farming.
Although vaccines against salmon lice have been described in the patent literature, see for example W02018035199 and others, no commercial vaccine are currently in use for treatment of fish, including salmon, infected by salmon lice.
There is a need for improved methods for treatment and prophylaxis of salmon lice infections in fish farming, and during the last 10 years there have been published sev-eral new patent families within the field. See for example W02020048945, W02019168406, W02019146827, W02019146826, W02019146825, W02019245891, W02019245722, W02019234396, W02019045573, W02019145730, W02019121900, W02019121887, W02019034694 and W02019031970.
The combination of light and drugs related to fish has been a topic in a few published scientific documents. Photodynannic therapy is generally a term for a therapy that in-volves a so-called photosensitizer and light, and oxygen, where the light activates the photosensitizer to generate singlet oxygen and other reactive and toxic species. Pho-todynamic therapy is well described in human medicine, see for example:
Kwiatkowski S et al., 2018, Photodynamic therapy - mechanisms, photosensitizers and combina-tions. Biomed Pharmacother. 106:1098-1107. The clinical use of photodynamic thera-py is, however, limited to some specific indications; especially some skin diseases with products comprising 5-aminolevulinic acid methyl ester as photosensitizer, and age-
Azannethiphos is an organophosphatase inhibitor of acetylcholinesterase. Aza-methiphos is the active substance in the commercial product Azasure.
Deltamethrin is a pyrethrin that interferes with the nerve membrane function in salmon lice resulting in paralysis and death. Deltamethrin is the active drug substance in the commercial io product ALPHA MAX. Hydrogen peroxide has for many years been used to combat salmon lice infections in fish including salmon. The mechanism of action is probably related to an oxidative effect on lice components and the formation of oxygen emboli within the salmon lice.
Development of drug resistance is a general problem with farming of fish including salmon, and currently the development of resistance is known for all drug substances used in fish farming.
Although vaccines against salmon lice have been described in the patent literature, see for example W02018035199 and others, no commercial vaccine are currently in use for treatment of fish, including salmon, infected by salmon lice.
There is a need for improved methods for treatment and prophylaxis of salmon lice infections in fish farming, and during the last 10 years there have been published sev-eral new patent families within the field. See for example W02020048945, W02019168406, W02019146827, W02019146826, W02019146825, W02019245891, W02019245722, W02019234396, W02019045573, W02019145730, W02019121900, W02019121887, W02019034694 and W02019031970.
The combination of light and drugs related to fish has been a topic in a few published scientific documents. Photodynannic therapy is generally a term for a therapy that in-volves a so-called photosensitizer and light, and oxygen, where the light activates the photosensitizer to generate singlet oxygen and other reactive and toxic species. Pho-todynamic therapy is well described in human medicine, see for example:
Kwiatkowski S et al., 2018, Photodynamic therapy - mechanisms, photosensitizers and combina-tions. Biomed Pharmacother. 106:1098-1107. The clinical use of photodynamic thera-py is, however, limited to some specific indications; especially some skin diseases with products comprising 5-aminolevulinic acid methyl ester as photosensitizer, and age-
3 related macular degeneration with products comprising verteporfin as photosensitizer.
Many of the publications on photodynamic therapy relates to cancer and some publica-tions relate to infections, however, these diseases are not commonly treated by pho-todynamic therapy.
D-P Hader et al., 2016, Fighting fish parasites with photodynamically active chloro-phyllin. Parasitol. Res. 115: 2277-2283, describe a study where water-soluble chloro-phyllin was used. The result was "In Ichthyobodo, 2 pg/mL proved sufficient with sub-sequent simulated solar radiation to almost quantitatively kill the parasites, while in Dactylogyrus, a concentration of about 6 pg/mL was necessary. The LD50 value for this io parasite was 1.02 pg/mL. Trichodina could be almost completely eliminated at 2 pg/mL. Only in the parasitic crustacean Argulus, no killing could be achieved by a pho-todynamic reaction using chlorophyllin." The chlorophyllin was prepared from spinach and does not comprise copper.
Eliana Alves et al., 2015, Potential applications of porphyrins in photodynamic inacti-vation beyond the medical scope. J. Photochenn. and Photobiol. C:
Photochemistry Reviews, 22:34-57 is a general review publication within the field on photodynamic therapy. Figure 4 on page 43 in this publication illustrates generally a treatment pro-tocol for photodynamic treatment of infected fish. The text in page 43 refers to Elina Alves et al., 2011, Photodynamic antimicrobial chemotherapy in aquaculture;
photoin-zo activation studies if Vibrio fischeri in PLOS One 6, 6, e20970. The light is "solar irradia-tion from 380 to 700 nm consisting in 13 OSRAM lamps." The photosensitizer used in these studies is a porphyrin derivative.
Peter KJ Robertson et al., 2009, A new generation of biocides for control of crustacea in fish farms. 3. Photochem and Photobiol. B, 95: 58-63. This publication relates to the field of photodynamic therapy where light and a photosensitizer are used to generate toxic species. The photosensitizer was methylene blue or nuclear fast red, the marine species as a model organism in place of salmon lice was the marine copepod Acartia clause, the lamp was a 500W tungsten halogen lamp. The result showed that the ma-rine copepod mortality with methylene blue was high when the methylene blue con-centration was 1 micromolar or above at 1 hour light activation. With nuclear fast red as photosensitizer, there was not observed any mortality during 1 hour light activa-tion. All light sources used in the above discussed prior art relate to white light.
The invention has for its object to remedy or to reduce at least one of the drawbacks of the prior art, or at least provide a useful alternative to prior art. The object is
Many of the publications on photodynamic therapy relates to cancer and some publica-tions relate to infections, however, these diseases are not commonly treated by pho-todynamic therapy.
D-P Hader et al., 2016, Fighting fish parasites with photodynamically active chloro-phyllin. Parasitol. Res. 115: 2277-2283, describe a study where water-soluble chloro-phyllin was used. The result was "In Ichthyobodo, 2 pg/mL proved sufficient with sub-sequent simulated solar radiation to almost quantitatively kill the parasites, while in Dactylogyrus, a concentration of about 6 pg/mL was necessary. The LD50 value for this io parasite was 1.02 pg/mL. Trichodina could be almost completely eliminated at 2 pg/mL. Only in the parasitic crustacean Argulus, no killing could be achieved by a pho-todynamic reaction using chlorophyllin." The chlorophyllin was prepared from spinach and does not comprise copper.
Eliana Alves et al., 2015, Potential applications of porphyrins in photodynamic inacti-vation beyond the medical scope. J. Photochenn. and Photobiol. C:
Photochemistry Reviews, 22:34-57 is a general review publication within the field on photodynamic therapy. Figure 4 on page 43 in this publication illustrates generally a treatment pro-tocol for photodynamic treatment of infected fish. The text in page 43 refers to Elina Alves et al., 2011, Photodynamic antimicrobial chemotherapy in aquaculture;
photoin-zo activation studies if Vibrio fischeri in PLOS One 6, 6, e20970. The light is "solar irradia-tion from 380 to 700 nm consisting in 13 OSRAM lamps." The photosensitizer used in these studies is a porphyrin derivative.
Peter KJ Robertson et al., 2009, A new generation of biocides for control of crustacea in fish farms. 3. Photochem and Photobiol. B, 95: 58-63. This publication relates to the field of photodynamic therapy where light and a photosensitizer are used to generate toxic species. The photosensitizer was methylene blue or nuclear fast red, the marine species as a model organism in place of salmon lice was the marine copepod Acartia clause, the lamp was a 500W tungsten halogen lamp. The result showed that the ma-rine copepod mortality with methylene blue was high when the methylene blue con-centration was 1 micromolar or above at 1 hour light activation. With nuclear fast red as photosensitizer, there was not observed any mortality during 1 hour light activa-tion. All light sources used in the above discussed prior art relate to white light.
The invention has for its object to remedy or to reduce at least one of the drawbacks of the prior art, or at least provide a useful alternative to prior art. The object is
4 achieved through features, which are specified in the description below and in the claims that follow.
Summary of the present invention The invention relates to a new method for treatment of salmon lice (L.
salmonis, C.
rogercresseyi, Caligus spp.) in farmed fish such as Atlantic salmon (S. salar L.) using an artificial light source and at least one chemical substance at toxicologically ac-ceptable concentrations for Atlantic salmon. More specifically, the present inventors have identified a novel therapy for the treatment of salmon louse in farmed Atlantic salmon populations that comprises a combination of artificial light together with water-io tetrapyrrole compounds with the proviso that the water-soluble tetrapyrrole compound is not chlorophyllin. Chlorophyll is not a water-soluble tetrapyrrole com-pound.
The fish may be a salmonid fish, such as Atlantic salmon (Salmo salar L.) or rainbow trout (Oncorhynchus mykiss). For convenience fish is referred to as Atlantic salmon or salmon in the preceding text and in the text to follow, however, without excluding rainbow trout, other salmonid species or other relevant fish species. The invention is defined by the independent patent claims. The dependent claims define advantageous embodiments of the invention.
The most preferred artificial light sources, according to the present invention, gener-ate blue light. In the present description blue light comprises violet light (380nm to 450 nm, blue light (450nm to 485nm) and cyan light (485nm to 500nm). Blue light as used herein covers the wavelength from 380nm to 500nnn.
The additional most preferred artificial light sources, according to the present inven-tion, generate red light. Red light as used herein covers the wavelength from 625nm to 740nm.
More specifically, the invention relates to a composition in the form of an aqueous so-lution comprising a chemical compound for use in a method of therapy using artificial light for an external crustacean parasite infection in salmonid fish, said external crus-tacean parasite infection comprises an infection of salmon lice, Lepeophtheirus salm-onis, Caligus rogercresseyi and Caligus spp. Said chemical compound is a water-soluble tetrapyrrole compound or a pharmaceutical acceptable derivative thereof, with the proviso that the water-soluble tetrapyrrole compound is not chlorophyllin or a de-rivative of chlorophyllin.
Said composition is administered in a bath treatment of the salmonid fish in need of such treatment, and the salmon lice is illuminated by artificial light.
In one embodiment said water-soluble tetrapyrrole compound may be a water-soluble tetrapyrrole derivative such as a toxicologically acceptable salt. In one embodiment
Summary of the present invention The invention relates to a new method for treatment of salmon lice (L.
salmonis, C.
rogercresseyi, Caligus spp.) in farmed fish such as Atlantic salmon (S. salar L.) using an artificial light source and at least one chemical substance at toxicologically ac-ceptable concentrations for Atlantic salmon. More specifically, the present inventors have identified a novel therapy for the treatment of salmon louse in farmed Atlantic salmon populations that comprises a combination of artificial light together with water-io tetrapyrrole compounds with the proviso that the water-soluble tetrapyrrole compound is not chlorophyllin. Chlorophyll is not a water-soluble tetrapyrrole com-pound.
The fish may be a salmonid fish, such as Atlantic salmon (Salmo salar L.) or rainbow trout (Oncorhynchus mykiss). For convenience fish is referred to as Atlantic salmon or salmon in the preceding text and in the text to follow, however, without excluding rainbow trout, other salmonid species or other relevant fish species. The invention is defined by the independent patent claims. The dependent claims define advantageous embodiments of the invention.
The most preferred artificial light sources, according to the present invention, gener-ate blue light. In the present description blue light comprises violet light (380nm to 450 nm, blue light (450nm to 485nm) and cyan light (485nm to 500nm). Blue light as used herein covers the wavelength from 380nm to 500nnn.
The additional most preferred artificial light sources, according to the present inven-tion, generate red light. Red light as used herein covers the wavelength from 625nm to 740nm.
More specifically, the invention relates to a composition in the form of an aqueous so-lution comprising a chemical compound for use in a method of therapy using artificial light for an external crustacean parasite infection in salmonid fish, said external crus-tacean parasite infection comprises an infection of salmon lice, Lepeophtheirus salm-onis, Caligus rogercresseyi and Caligus spp. Said chemical compound is a water-soluble tetrapyrrole compound or a pharmaceutical acceptable derivative thereof, with the proviso that the water-soluble tetrapyrrole compound is not chlorophyllin or a de-rivative of chlorophyllin.
Said composition is administered in a bath treatment of the salmonid fish in need of such treatment, and the salmon lice is illuminated by artificial light.
In one embodiment said water-soluble tetrapyrrole compound may be a water-soluble tetrapyrrole derivative such as a toxicologically acceptable salt. In one embodiment
5 said water-soluble tetrapyrrole compound may be a water-soluble tetrapyrrole com-pound in the form of a toxicologically acceptable cyclodextrin complex.
In one embodiment said water-soluble tetrapyrrole compound may be a member of a group of porphyrins, or an acceptable pharmaceutical derivative thereof. In one em-bodiment said water-soluble tetrapyrrole compound is a member of a group of chlo-or an acceptable pharmaceutical derivative thereof. In one embodiment said wa-ter-soluble tetrapyrrole compound is a member of a group of bacteriochlorins, or an acceptable pharmaceutical derivative thereof. In one embodiment said water-soluble tetrapyrrole compound is a member of a group of phthalocyanines, or an acceptable pharmaceutical derivative thereof.
In one embodiment said artificial light may be blue light. In an alternative embodi-ment said artificial light may be red light. The most preferred light is blue light. In an alternative embodiment said artificial light is a combination of blue light and red light.
In one embodiment source of artificial light may comprise of LED lamps. In one em-bodiment said artificial light source may comprise of a laser light system.
The laser light system may be a laser light system targeting the salmon lice present on the fish, or the laser light system may be a laser light system that do not target salmon lice present on the fish.
The salmonid fish may be located in a receptacle. The receptacle may be one of a closed tank, a semi-closed tank, a chamber, a container, and a fishpond. The salmonid fish may be located in one of an ocean cage and a net pen.
The blue light source may comprise of LED lamps. The LED lamps may emit light of a wavelength of 380nnn to 500nnn, for example around 450 to 460 nnn. Said water-soluble tetrapyrrole compound may be added in the water surrounding the salmonid fish. The water surrounding the salmonid fish may form the bath treatment.
In a second aspect the invention relates to a method for use of a composition as de-scribed above, wherein the method of therapy comprises use of artificial light. Said method may be a photodynannic method. The method may comprise using a water-
In one embodiment said water-soluble tetrapyrrole compound may be a member of a group of porphyrins, or an acceptable pharmaceutical derivative thereof. In one em-bodiment said water-soluble tetrapyrrole compound is a member of a group of chlo-or an acceptable pharmaceutical derivative thereof. In one embodiment said wa-ter-soluble tetrapyrrole compound is a member of a group of bacteriochlorins, or an acceptable pharmaceutical derivative thereof. In one embodiment said water-soluble tetrapyrrole compound is a member of a group of phthalocyanines, or an acceptable pharmaceutical derivative thereof.
In one embodiment said artificial light may be blue light. In an alternative embodi-ment said artificial light may be red light. The most preferred light is blue light. In an alternative embodiment said artificial light is a combination of blue light and red light.
In one embodiment source of artificial light may comprise of LED lamps. In one em-bodiment said artificial light source may comprise of a laser light system.
The laser light system may be a laser light system targeting the salmon lice present on the fish, or the laser light system may be a laser light system that do not target salmon lice present on the fish.
The salmonid fish may be located in a receptacle. The receptacle may be one of a closed tank, a semi-closed tank, a chamber, a container, and a fishpond. The salmonid fish may be located in one of an ocean cage and a net pen.
The blue light source may comprise of LED lamps. The LED lamps may emit light of a wavelength of 380nnn to 500nnn, for example around 450 to 460 nnn. Said water-soluble tetrapyrrole compound may be added in the water surrounding the salmonid fish. The water surrounding the salmonid fish may form the bath treatment.
In a second aspect the invention relates to a method for use of a composition as de-scribed above, wherein the method of therapy comprises use of artificial light. Said method may be a photodynannic method. The method may comprise using a water-
6 soluble tetrapyrrole compound or a pharmaceutical acceptable derivative thereof as a photosensitizer.
The artificial light may be blue light. The source of artificial light comprises of LED
lamps. The artificial light may be red light. The method of therapy comprises salmonid fish located in a receptacle. The method of therapy comprises salmonid fish located in an ocean cage or a net pen.
The energy required for the artificial light source according to the present invention can vary from a few watts to several kilowatts depending upon the nature of the artifi-cial light source and the volume of the enclosure or ocean cage or net. The intensity of io the light diminishes with the distance between the light source and the target surface, e.g. the surface of the salmon lice. In some cases, and for some useful water-soluble tetrapyrrole compounds, such as positively charged tetrapyrrole compounds or a pharmaceutical acceptable salt thereof, or negatively charged tetrapyrrole compounds or a pharmaceutical acceptable salt thereof, or hydrophilic neutral tetrapyrrole com-pounds or pharmaceutical acceptable derivates thereof, the light intensity may be too high at a too close distance, leading to a too rapid bleaching of the water-soluble tetrapyrrole compound, and thereby the water-soluble tetrapyrrole compound lose its effect. In some cases, and for some useful water-soluble tetrapyrrole compounds, the light intensity may be too low at a too far distance, leading to that water-soluble zo tetrapyrrole compound is not activated. It is therefore within the scope of the present invention to optimize the distance between the artificial light source and the salmon lice. The optimal distance is thus dependent on among other things the actual wave-length, the actual water-soluble tetrapyrrole compound, and the actual specification of the lamp, e.g. output in lumen.
The light may comprise of a single light source or a plurality of light sources in a given three-dimensional geometric system to secure optimal efficacy for treatment of fish infected with salmon lice. The light may be placed in air above the bath with fish in-fected with salmon lice, however, if the volume is large, as with an ocean cage, the light is preferably placed under water. A combination of light above and under water may in some cases be useful. The artificial light source may optionally be placed relat-ed to a device where the fish can obtain a fixed dose of light. A typical device where the fish get a fixed dose of light could, for example, be a system comprising of pipes and baths where the water with infected fish is pumped through pipes and kept in baths during light irradiation. For some procedures it might be an advantage to use a combination of blue and red light as an alternative to blue light or red light alone.
The artificial light may be blue light. The source of artificial light comprises of LED
lamps. The artificial light may be red light. The method of therapy comprises salmonid fish located in a receptacle. The method of therapy comprises salmonid fish located in an ocean cage or a net pen.
The energy required for the artificial light source according to the present invention can vary from a few watts to several kilowatts depending upon the nature of the artifi-cial light source and the volume of the enclosure or ocean cage or net. The intensity of io the light diminishes with the distance between the light source and the target surface, e.g. the surface of the salmon lice. In some cases, and for some useful water-soluble tetrapyrrole compounds, such as positively charged tetrapyrrole compounds or a pharmaceutical acceptable salt thereof, or negatively charged tetrapyrrole compounds or a pharmaceutical acceptable salt thereof, or hydrophilic neutral tetrapyrrole com-pounds or pharmaceutical acceptable derivates thereof, the light intensity may be too high at a too close distance, leading to a too rapid bleaching of the water-soluble tetrapyrrole compound, and thereby the water-soluble tetrapyrrole compound lose its effect. In some cases, and for some useful water-soluble tetrapyrrole compounds, the light intensity may be too low at a too far distance, leading to that water-soluble zo tetrapyrrole compound is not activated. It is therefore within the scope of the present invention to optimize the distance between the artificial light source and the salmon lice. The optimal distance is thus dependent on among other things the actual wave-length, the actual water-soluble tetrapyrrole compound, and the actual specification of the lamp, e.g. output in lumen.
The light may comprise of a single light source or a plurality of light sources in a given three-dimensional geometric system to secure optimal efficacy for treatment of fish infected with salmon lice. The light may be placed in air above the bath with fish in-fected with salmon lice, however, if the volume is large, as with an ocean cage, the light is preferably placed under water. A combination of light above and under water may in some cases be useful. The artificial light source may optionally be placed relat-ed to a device where the fish can obtain a fixed dose of light. A typical device where the fish get a fixed dose of light could, for example, be a system comprising of pipes and baths where the water with infected fish is pumped through pipes and kept in baths during light irradiation. For some procedures it might be an advantage to use a combination of blue and red light as an alternative to blue light or red light alone.
7 Surprisingly it has been found that not only do artificial light and water-soluble tetrapyrrole compounds according to the present invention together have an additional effect on salmon lice but that light from an artificial light source and water-soluble tetrapyrrole together have a synergistic effect. The exact mechanism of the combina-tion of light together with the water-soluble tetrapyrrole compounds on salmon lice is not studied, but it can be speculated that the artificial light activates the water-soluble tetrapyrrole compounds through a photochemical process and that the formed reactive species are responsible for the observed increased toxicity on the salmon lice. This mode of action is seen in photodynamic therapy. The water-soluble tetrapyrrole corn--10 pound and derivates thereof may act as a photosensitizer. The inventors have per-formed some simple experiments related to light penetration through lice and salmon skin. The overall conclusion is the unexpected result that light easily penetrate salmon lice while light of different wave lengths do not penetrate salmon skin. Based on this result and the speculated mechanism of action discussed above, the method described herein seems to be effective to kill salmon lice with an acceptable toxicity for the fish.
Said water-soluble tetrapyrrole compound may comprise a water-soluble tetrapyrrole derivative. Said water-soluble tetrapyrrole derivative may be a toxicologically accepta-ble salt of a tetrapyrrole compound. By the term "toxicologically acceptable"
in this text is meant that the aqueous concentration of the tetrapyrrole compound used to treat lice, is acceptable for the fish. The adverse events for the fish by applying the present treatment are equal to or less than adverse events seen in other state of the art methods for treatment of salmon lice infected fish. Said water-soluble tetrapyrrole derivative may be in the form of a cyclodextrin complex where the cyclodextrin com-plex comprises a water-soluble tetrapyrrole compound.
The said water-soluble tetrapyrrole compound can be a derivative comprising one or more salt-forming functional groups or one or more neutral hydrophilic groups.
The artificial light source may comprise of LED lamps. The wavelength of the emitted light from the artificial light source may be between 200 and 800nm. The wavelength of the emitted light may be between 400 and 800nm. The wavelength of the emitted light may be between 200 and 400nm. The wavelength of the emitted light may be between 200 and 300nm.
Said artificial light source, for example a laser, may be a part of a device for automatic localization of salmon lice. Said artificial light source may be a light source used in cultivation or farming of salmonid fish. Said water-soluble tetrapyrrole compound may be added in a food pellet for feeding the salmonid fish. Said water-soluble tetrapyrrole
Said water-soluble tetrapyrrole compound may comprise a water-soluble tetrapyrrole derivative. Said water-soluble tetrapyrrole derivative may be a toxicologically accepta-ble salt of a tetrapyrrole compound. By the term "toxicologically acceptable"
in this text is meant that the aqueous concentration of the tetrapyrrole compound used to treat lice, is acceptable for the fish. The adverse events for the fish by applying the present treatment are equal to or less than adverse events seen in other state of the art methods for treatment of salmon lice infected fish. Said water-soluble tetrapyrrole derivative may be in the form of a cyclodextrin complex where the cyclodextrin com-plex comprises a water-soluble tetrapyrrole compound.
The said water-soluble tetrapyrrole compound can be a derivative comprising one or more salt-forming functional groups or one or more neutral hydrophilic groups.
The artificial light source may comprise of LED lamps. The wavelength of the emitted light from the artificial light source may be between 200 and 800nm. The wavelength of the emitted light may be between 400 and 800nm. The wavelength of the emitted light may be between 200 and 400nm. The wavelength of the emitted light may be between 200 and 300nm.
Said artificial light source, for example a laser, may be a part of a device for automatic localization of salmon lice. Said artificial light source may be a light source used in cultivation or farming of salmonid fish. Said water-soluble tetrapyrrole compound may be added in a food pellet for feeding the salmonid fish. Said water-soluble tetrapyrrole
8 compound may be added in the water surrounding the salnnonid fish. An artificial light device may be used according to the methods described above.
The present invention may relate to a treatment of salmon louse in farmed fish popu-lations that comprises a combination of water-soluble tetrapyrrole compounds accord-ing to the present invention and artificial light.
The present invention may relate to a protocol for the present treatment.
Suitably, the water-soluble tetrapyrrole compound is administered prior to, after or at approximate-ly the same time as the artificial light.
The present invention may relate to a protocol for the present treatment. The present io treatment can be performed when the Atlantic salmon is in receptacles or enclosures, e.g. closed tanks or semi-closed tanks, pipes, chambers, containers, fishponds, ocean cages or net pens or a combination of such enclosures.
The present invention may relate to the artificial light source. The light source accord-ing to the present invention can be a light source positioned in the air or placed in wa-"1 5 ter. The light source can optionally be a plurality of light sources.
The light source should generate light with wave lengths from 200 to 800nnn. The light source might also generate electromagnetic radiation that is outside this range. The light source might be in the form of a laser. The light source or light systems may comprise halo-gen lamps, mercury lamps, light emitting diodes (LEDs) or other suitable light sys-20 terns. The light source can be a stationary light source or a movable light source.
The present invention may relate to a drug treatment protocol. Optionally, according to the present invention other drug substances or drug like compounds might, in addi-tion to the water-soluble tetrapyrrole, be useful for the treatment according to the present invention. These drugs include other drugs that have been shown to be toxic 25 to salmon lice including commercial products that are approved for salmon lice infec-tions in Atlantic salmon.
The present invention may relate to the dose or concentration of water-soluble tetrapyrrole or pharmaceutically acceptable salts thereof in the clinical situation.
The present invention may relate to the exposure time of the treatment process. The 30 time necessary to perform the present process varies from minutes to hours depend-ing upon several factors like for example nature of the salmon lice infection, number of Atlantic salmon per cubic meter of water, concentration of the water-soluble
The present invention may relate to a treatment of salmon louse in farmed fish popu-lations that comprises a combination of water-soluble tetrapyrrole compounds accord-ing to the present invention and artificial light.
The present invention may relate to a protocol for the present treatment.
Suitably, the water-soluble tetrapyrrole compound is administered prior to, after or at approximate-ly the same time as the artificial light.
The present invention may relate to a protocol for the present treatment. The present io treatment can be performed when the Atlantic salmon is in receptacles or enclosures, e.g. closed tanks or semi-closed tanks, pipes, chambers, containers, fishponds, ocean cages or net pens or a combination of such enclosures.
The present invention may relate to the artificial light source. The light source accord-ing to the present invention can be a light source positioned in the air or placed in wa-"1 5 ter. The light source can optionally be a plurality of light sources.
The light source should generate light with wave lengths from 200 to 800nnn. The light source might also generate electromagnetic radiation that is outside this range. The light source might be in the form of a laser. The light source or light systems may comprise halo-gen lamps, mercury lamps, light emitting diodes (LEDs) or other suitable light sys-20 terns. The light source can be a stationary light source or a movable light source.
The present invention may relate to a drug treatment protocol. Optionally, according to the present invention other drug substances or drug like compounds might, in addi-tion to the water-soluble tetrapyrrole, be useful for the treatment according to the present invention. These drugs include other drugs that have been shown to be toxic 25 to salmon lice including commercial products that are approved for salmon lice infec-tions in Atlantic salmon.
The present invention may relate to the dose or concentration of water-soluble tetrapyrrole or pharmaceutically acceptable salts thereof in the clinical situation.
The present invention may relate to the exposure time of the treatment process. The 30 time necessary to perform the present process varies from minutes to hours depend-ing upon several factors like for example nature of the salmon lice infection, number of Atlantic salmon per cubic meter of water, concentration of the water-soluble
9 tetrapyrrole or pharmaceutically acceptable salts thereof in the water and optionally other drugs and drug like compounds and nature of the artificial light source.
The present invention may relate to resistance. The method according to the present invention is new for treatment of Atlantic salmon infected by salmon lice and has ad-vantages related to treatment of Atlantic salmon infected by resistant salmon lice and also related to generation of new forms of resistance. The possible mechanism of ac-tion related to the present invention is biologically not a typical process where re-sistance processes are generated.
The advantages by a combination of artificial light together with water-soluble tetrapyrrole compounds according to the present invention versus state-of-the-art treatment of salmon lice relate to one or more of the following topics:
reduced amount of drugs, improved efficacy on salmon lice, reduced toxicity to the Atlantic salmon, resistance issues, cost and time.
Detailed description of the present invention Surprisingly it has been found a new method for treatment of salmon lice (L.
salmonis and C. rogercresseyi, Caligus spp.) in farmed fish such as Atlantic salmon (S.
salar L.) using an artificial light source and at least one chemical substance at toxicologically acceptable concentrations for Atlantic salmon.
The present invention relates to water-soluble tetrapyrrole compounds. More specifi-cally, the invention relates in a first aspect to a composition in the form of an aqueous solution comprising a tetrapyrrole for use in a method of therapy using artificial light for an external crustacean parasite infection in salmonid fish, said external crustacean parasite infection comprises an infection of salmon lice, Lepeophtheirus salmon/s1 Ca-ligus rogercresseyi and Caligus spp.
In one embodiment said water-soluble tetrapyrrole compound for use in a method of photodynamic therapy for an external crustacean parasite infection in salmonid fish is a water-soluble tetrapyrrole compound comprising one or more basic groups, such as aliphatic amino groups, or permanently charged nitrogen-comprising groups such as quaternary ammonium salts, one or more acidic groups such as sulfonic acid groups, phosphate groups or carboxylic groups, and/or one or more neutral hydrophilic groups like alcohols, phenols and/or polyethylene glycol.
The term "water-soluble tetrapyrrole compound" is herein any form of the tetrapyrrole compound on neutral or charged form. If the water-soluble tetrapyrrole compound is on charged form, the compound is in the form of a salt. Water-soluble tetrapyrrole salts are, according to the present invention any salt that is sufficient soluble in sea water, are toxic to salmon lice and are not toxic for fish including salmon with or with-out light. For tetrapyrroles with basic groups typical salts are formed with acids like hydrochloric acid, sulfuric acid, phosphoric acid, succinic acid and other typical non-5 toxic acids used in pharmaceuticals for veterinary or human use. For tetrapyrroles with acidic groups typical salts are formed with bases like sodium hydroxide, calcium hydroxide, magnesium hydroxide, amine salts and other typical non-toxic bases used in pharmaceuticals for veterinary or human use. The term "water-soluble tetrapyrrole compound" can also be the tetrapyrrole derivative (as salt or not as salt) in the form io of a complex with cyclodextrin.
The chemical group called cyclodextrin (CD) includes alpha-CD which is a 6-membered sugar ring molecule, beta-CD which is a 7-membered sugar ring molecule, gamma-CD
which is a 7-membered sugar ring molecule and an almost unlimited number of chem-ical derivatives with various degree of substitution on these three different sugar ring molecules.
Among the preferred water-soluble tetrapyrrole compounds according to the present invention are the corresponding cyclodextrin complexes. Regarding the cyclodextrin part of the water-soluble tetrapyrrole compound of cyclodextrin complexes are the following cyclodextrins preferred: unsubstituted cyclodextrin, methyl cyclodextrin and zo 2-hydroxypropyl cyclodextrin, and sulphobutyl-cyclodextrin. The most preferred cy-clodextrins have a 7-membered sugar ring molecular structure.
The term "water-soluble tetrapyrrole compound" also includes compounds where the tetrapyrrole ring system incorporates a metal ion.
Very many photoactive compounds described in the scientific literature are so-called "tetrapyrroles". This term relates to cyclic compounds comprising four 5-membered rings comprising a nitrogen atom. A typical tetrapyrrole core is porphyrin shown be-low.
\
-NH N-/
--N FINJ
Porphyrin The tetrapyrrole structures can be with various degrees of chemical double bonds as shown below forming different chemical ring structures. Chlorins and bacteriochlorins are reduced versions of porphyrin often referred to as hydroporphyrins.
Chlorins have one reduced double bond while bacteriochlorins have two reduced double bonds.
In phthalocyanines the four pyrrole ring structures are condensed with benzene rings.
The tetrapyrrole ring structure might optionally be condensed with other ring systems then benzene rings; for example a heterocyclic ring like pyridine.
/ ---- \ <,-.-,..--'''''."--=
NH N ' -NH N- ';----Nti N:=---',4,, / \ t ------N HN \ I \
\ . ',--r?4,<14-,..f.;.=
\ --...., --.......
Porphyrin Chlorin Bacteriochlorin <
:1 ,, -A His4----,i re , N
0 f Phthalocyanine The present invention relates to water-soluble tetrapyrrole compounds with or without additional ring systems. Methods for synthesis of water-soluble derivatives are well io described in the scientific literature and patent literature, e.g.
EP2464384. See for example Michael Luciano et al., 2017, Modifications of porphyrins and hydroporphyrins for their solubilization in aqueous media in Molecules: 22, 980, and references herein.
The abovementioned functional groups might be attached directly or indirectly to the tetrapyrrole ring or might be incorporated or attached to an additional ring system.
Talporfin is a substance in a drug (LaserphyrinC)) for treatment of lung cancer in hu-mans in Japan. Talporfin is a chlorin derivative. This is an example where three of four water-solubilizing groups, i.e. four acidic groups are indirectly bond to the tetrapyrrole derived ring system and one acidic group is directly bond.
HO
= 0 /N HN
N
Talporfin Tennoporfin is the substance in a drug (Foscan 10) for treatment of head and neck can-cer in humans. This is an example where the solubilizing phenolic groups are attached to an additional ring system. Phthalocyanines can also be modified to become water-soluble compounds by covalent attachment of water-solubilizing functional groups di-rectly or indirectly to additional rings.
N HO HN
) OH
Tennoporfin Some preferred water-soluble tetrapyrrole compounds to be used according to the present invention include:
= Tetrapyrrole compounds with carboxylate functional groups (typically 1 to carboxylic groups), except for chlorophyllin.
= Sulfonated tetrapyrrole compounds, typically with one to four sulphonic acid groups = Phosphate/phosphonate tetrapyrrole compounds, typically with one to six phosphate and/or phosphonate groups = 4-pyridinium-tetrapyrrole compounds, typically with one to four pyridinium groups = Other pyridyl-substituted tetrapyrrole compounds = Imidazolium-tetrapyrrole compounds = Tetrapyrrole compounds comprising alcohol, phenol, ether; typically PEGylated tetrapyrrole; typically with more than one oxygen-comprising functional group The above-mentioned compounds are preferably in the form of a pharmaceutically acceptable salt if the tetrapyrrole compound comprises one or more acidic and/or basic group. For a given tetrapyrrole salt, the stoichionnetric ratio between the ions might vary; for example, a tetrapyrrole phosphate ester might be in the form of monosodium salt or disodium salt.
The water-soluble tetrapyrrole compounds according to the present invention are easi-ly available:
= Several compounds are commercially available from different vendors.
= Very many compounds are described in the scientific literature and patent liter-ature with synthetic methods and chemical characterization methods and data.
= A person skilled in the art can utilize standard organic methods for preparation of compounds.
The present invention does not claim any new chemical compounds per se.
Salts of water-soluble tetrapyrrole compounds can easily be prepared by standard methods using an acidic compound and a basic compound. Such methods typically include mixing of relevant molecular ratios of acids and bases in an appropriate sol-vent, optionally heating and then isolation by evaporation or precipitation.
The water-soluble salt is dried using standard methods; air drying, head drying, vacuum drying and spray drying. The water-soluble tetrapyrrole cyclodextrin complexes according to the present invention can be prepared by standard methods for preparation of such complexes. These methods include co-evaporation, spray-drying, freeze drying and kneading. One simple method is to carefully mix the water-soluble tetrapyrrole with the cyclodextrin (typically molar ratio 1 to 5) with small amounts of water forming a very thick paste for 10 minutes using a mortar and pestle, dry the paste in an oven and prepare a powder of the dry material using the mortar and pestle.
The actual aqueous concentration of water-soluble tetrapyrrole compounds in the clini-cal situation to remove salmon lice from fish, varies depending upon the various pa-rameters like for example choice of water-soluble tetrapyrrole compound, tempera-ture, disease stage, light source and the density of Atlantic salmon. Typical concentration range for the water-soluble tetrapyrrole compound according to the pre-sent invention is in the range of 0.01 micromolar (10-8 M) to 400 micromolar (400 times 10-6 M). More preferred the concentration range for the water-soluble tetrapyrrole compounds according to the present invention is in the range 0.1 mi-cromolar to 200 micromolar.
The present invention relates to treatment of salmon louse in farmed fish populations that comprises a combination of water-soluble tetrapyrrole compounds and light from an artificial light source.
The present invention relates to a protocol for the present treatment.
Suitably, water-soluble tetrapyrrole compound(s) are administered prior to, after or at approximately the same time as the light.
The light might be present after the water-soluble tetrapyrrole compound concentra-tion around the Atlantic salmon is reduced. Any protocol using water-soluble tetrapyrrole and light is within the scope of the present invention. It is up to the io skilled person on salmon lice treatment to select the best suited protocol for each treatment.
A first preferred protocol is to apply the water-soluble tetrapyrrole some time prior to the light treatment. In this case the light and the water-soluble tetrapyrrole are pre-sent partly together and optionally continue to use light after the aqueous concentra-tion of the water-soluble tetrapyrrole is reduced.
A second preferred protocol is to apply water-soluble tetrapyrrole and artificial light treatment together and optionally continue to use light after the aqueous concentra-tion of the water-soluble tetrapyrrole is reduced.
A third preferred protocol is to apply light after the aqueous concentration of the wa-ter-soluble tetrapyrrole is reduced but the water-soluble tetrapyrrole still is present within the salmon lice.
The most preferred protocol is to apply light, at least partly, when the concentration of the water-soluble tetrapyrrole compounds still is quite high in the water surrounding the Atlantic salmon and the salmon lice.
The present invention relates to a protocol for the present treatment. The present treatment can be performed when the Atlantic salmon is in receptacles or enclosures, e.g. closed tanks or semi-closed tanks, pipes, chambers, containers, fishponds, ocean cages or net pens or a combination of such enclosures.
The preferred methods of the present invention relate to treatment of Atlantic salmon with salmon lice within a tank/boat or ocean cages or net pens. The absolutely most preferred methods of the present invention relate to treatment of Atlantic salmon in-fected with salmon lice within an ocean cage or a net pen.
The present invention relates to the position of the artificial light source.
One preferred position of the light source is in the air above the water. Another preferred position of the light source is on the walls or the bottom of a receptacle or enclosure, e.g. closed tank or semi-closed tank, pipe, chamber, container, or fishponds. Another preferred 5 position of the light source is under water within the receptacle or the ocean cage or net by mechanical arrangements and/or floating devices. The most preferred position of the light source in a large ocean cage or net is under water.
The artificial light source should generate light that has wave lengths from 200nm to 800nm. One preferred artificial light source according to the present invention is that io the artificial light source generates visible light within the wavelength band from 400nm to 800nm.
One preferred artificial light source according to the present invention is that the artifi-cial light source generates light within one of the following colors: red, yellow, green, or blue. The artificial light source may generate white light.
15 Another preferred light source according to the present invention is that the artificial light source generates UV light within the wavelength band from 200nm to 400nm.
Another preferred artificial light source according to the present invention is that the artificial light source generates UVC light within the wavelength band from 200nm to 300nm.
The artificial light source might also generate electromagnetic radiation that is outside these wavelength bands. If so, the artificial light source must also generate some light within referred wave lengths or colors.
The artificial light source can be one single artificial light source or a plurality of artifi-cial light sources. If the volume is huge, like in an ocean cage or net, it is according to the present invention preferred to use a plurality of artificial light sources.
One artificial preferred light source according to the present invention is that the artifi-cial light source is based on laser.
Another preferred artificial light source according to the present invention is that the artificial light source is based on LEDs, halogen lamp or mercury lamp. The most pre-ferred type of lamps among these lamps are LED lamps.
The most preferred artificial light sources according to the present invention are LED
lamps generating blue light; typically, in the wavelength range from 380nm to 500nm.
Examples of such lamps are optionally dimmable, underwater lamps currently com-mercially available and used in aquaculture for other purposes.
The light from the artificial light source may be stationary, i.e. same light in the same area over time, or the artificial light source may be movable.
The present invention relates to a drug treatment protocol. Optionally, according to the present invention, other drug substances or drug like compounds may, in addition to water-soluble tetrapyrrole, be useful for the treatment according to the present invention. One preferred treatment protocol according to the present invention is that the other drug substances or drug like compounds are selected among other drugs io that are regulatory approved for use to treat Atlantic salmon infected by salmon lice.
Another preferred treatment protocol according to the present invention is that the other drug substances or drug like compounds that are cholinesterase inhibitors, syn-thetic pyrethroids, chitin synthase inhibitors or glutamate-based chlorine ion channel regulators.
Another preferred treatment protocol according to the present invention is that the other drug substances or drug like compounds are selected among compounds that are water-soluble tetrapyrrole compounds. Another preferred treatment protocol ac-cording to the present invention is that the other drug substances or drug like com-pounds are selected among compounds that are phototoxic.
The present invention relates to the dose or concentration of the water-soluble tetrapyrrole in the clinical situation.
The present invention relates to the timing of the treatment process. The time neces-sary to perform the present process varies from minutes to hours depending upon several factors like for example nature of the salmon lice infection, number of Atlantic salmons per cubic meter, the nature and the concentration of the water-soluble tetrapyrrole and optionally other drugs and drug like compounds, and nature of the light source.
The present invention relates to resistance. The method according to the present in-vention is new for treatment of Atlantic salmon infected by salmon lice and has ad-vantages related to treatment of Atlantic salmon infected by resistant salmon lice and also relates to generation of new forms of resistance. The possible mechanism of ac-tion related to the present invention is biologically not a typical process where re-sistance processes are generated.
The present invention relates to compositions. The composition might be in the form of liquid concentrated solution or in the form of a solid powder. The concentrated solu-tion is diluted with sea water before use. The solid powder is typically dissolved to a concentrated solution and further diluted with sea water before use or optionally dis-solved directly in sea water. The solutions comprise one or more solvents. The sol-vents are selected among toxicologically acceptable solvents or solvent mixtures typi-cally for example selected from water, sea water, ethanol, isopropanol, glycerol, dimethyl sulfoxide, dimethyl fornnannide, acetone and low molecular weight polyeth-ylene glycols. The concentrate might typically comprise additional non-toxic additives io like surfactants and solubilizers used in pharmaceutical compositions for human and animal medical products. These additives include polysorbates like for example Poly-sorbate 20 and Polysorbate 80, polyoxyethylene (PEG) castor oil derivatives, polyox-anners, glycerol esters and other ionic and non-ionic surfactants and solubilizers. An-ionic surfactants are, according to the present invention, the most preferred group of ionic surfactants. However, the most preferred surfactants, according to the present invention, are non-ionic surfactants. Both ionic and non-ionic surfactants might work as solubilizers. The powder can be the water soluble tetrapyrrole active substance without any additives or a powder mixture comprising various additives. The additives to be optionally used in the present compositions include typical excipients used in pharmaceutical formulations like binders, carriers, coatings, diluents, disintegrants, stabilizers, surfactants, solubilizers and other typical pharmacologically inactive excipi-ents. Typical dry formulations are, according to the present invention, non-encapsulated dry powder (pure water-soluble tetrapyrrole derivatives or cyclodextrin derivatives thereof optionally mixed with additives), granulates comprising water-soluble tetrapyrrole derivatives or cyclodextrin derivatives thereof and dry powder or granulate comprising water-soluble tetrapyrrole derivatives or cyclodextrin derivatives thereof in water-soluble polymer bags, typically polyvinyl alcohol bags.
Granulates can typically be prepared using standard granulation methods for example well known in the field of tableting. For granulation methods see for example Dilip M.
Parikh (Ed.) Handbook of Pharmaceutical Granulation Technology, Second Edition (2005) Tay-lor&Francis Group, Florida, USA.
The advantages by a combination of light together with water-soluble tetrapyrrole de-fined in the present invention relate to one or more of the following topics:
reduced amount of drugs, reduction of environmental issues, no resistance development, im-proved efficacy on salmon lice, and reduced toxicity to the Atlantic salmon.
Experimental Example 1 Copper phthalocyanine-3,4',4",4m-tetrasulfonic acid tetrasodium salt - 2-hydroxypropyl-beta-cyclodextrin complex Copper phthalocyanine-3,4`,4",4"1-tetrasulfonic acid tetrasodium salt (Aldrich 5G SDS) (my 984.2, 492 mg, 0.5 mmol) and 2-hydroxypropyl-beta-cyclodextrin (Biosynth) (mw 1460, 3.65 g, 2.5 mmol) were mixed volumetrically in a mortar.
Wa-ter (2 ml) was added, and the blue paste was vigorously mixed in the mortar and then dried in an oven at 60 C for 24 hours. The content was pulverized in the mortar. The io title compound comprised 11.9 weight- k copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt.
Example 2 Copper phthalocyanine-3,4',4",4m-tetrasulfonic acid tetrasodium salt - beta-cyclodextrin sulfobutyl ether sodium salt complex Copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt (Aldrich 5G SDS) (my 984.2, 98 mg, 0.1 mmol) and beta-cyclodextrin sulfobutyl ether sodium salt (Biosynth 0C15979) (mw 2242, 2.24 g, 1 mmol) were mixed volumetrically in a mortar. Water (2 ml) was added, and the blue paste was vigorously mixed in the mor-tar and then dried in an oven at 60 C for 24 hours. The content was pulverized in the mortar. The title compound comprised 4.2 weight-% copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt.
Example 3 4,4',4",4"-(porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid) - be-ta-cyclodextrin sulfobutyl ether sodium salt complex 4,4',4",4"-(porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid) (Sigma-Aldrich)89456-100MG-F) (mw 935, 9 mg, 0.01 mmol) and beta-cyclodextrin sulfobutyl ether sodium salt (Biosynth 0C15979) (mw 2242, 0.22 g, 0.1 mmol) were mixed vol-umetrically in a mortar. Water (0.2 ml) was added, and the blue paste was vigorously mixed in the mortar and then dried in an oven at 60 C for 24 hours. The content was pulverized in the mortar. The title compound comprised 3.9 weight-% 4,4',4",4"-(porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid).
Example 4 Copper phthalocyanine-3,4',4",4--tetrasulfonic acid tetrasodium salt - gam-ma-cyclodextrin complex Copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt (Aldrich 5G SDS) (my 984.2, 492 mg, 0.5 mmol) and gamma-cyclodextrin (Wacker Fine Chemicals, Cavannax W8) (mw 1297, 2.40 g, 1.85 mmol) were mixed volumetrically in a mortar. Water (2 ml) was added, and the blue paste was vigorously mixed in the mortar and then dried in an oven at 60 C for 24 hours. The content was pulverized in the mortar. The title compound comprised 17 weight-% copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt.
Example 5 Copper phthalocyanine-3,4',4",4m-tetrasulfonic acid tetrasodium salt - beta-cyclodextrin complex Copper phthalocyanine-3,4',4",4"1-tetrasulfonic acid tetrasodium salt (Aldrich 5G SDS) (my 984.2, 492 mg, 0.5 mmol) and beta-cyclodextrin (Wacker Fine Chemi-cals, Cavamax W7 (mw 1135, 3,405g, 3 mmol) were mixed volumetrically in a mortar.
Water (2 ml) was added, and the blue paste was vigorously mixed in the mortar and then dried in an oven at 60 C for 24 hours. The content was pulverized in the mortar.
The title compound comprised 11.9 weight-% copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt.
Example 6 Phthalocyanine concentrate for dilution before use Copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt 500 gram Macrogol glycerol ricinolaeate 15 gram Polysorbate 80 10 gram N-nnethylpyrrolidon ad. 5 liter A stirred mixture of macrogol glycerol ricinolaeate, polysorbate 80 and N-methylpyrrolidone (3 liter) are heated to 60 'C. Copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt is added. Additional N-methylpyrrolidon to a total volume of 5 liter is added and the mixture was stirred for 10 minutes, cooled and filled on one-liter bottles. One liter comprises 100 gram copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt.
Example 7 Bag comprising dry powder of porphine - cyclodextrin complex 4,4',4",4"'-(porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid) - beta-cyclodextrin sulfobutyl ether sodium salt complex 100 gram 5 Kaolin 350 gram Silica 50 gram The components are volumetrically mixed and filled into polymer bags made from polvinylalcohol. Each bag comprises 100 gram dry powder (20 gram 4,4',4",4"-(porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid) - beta-cyclodextrin sul-
The present invention may relate to resistance. The method according to the present invention is new for treatment of Atlantic salmon infected by salmon lice and has ad-vantages related to treatment of Atlantic salmon infected by resistant salmon lice and also related to generation of new forms of resistance. The possible mechanism of ac-tion related to the present invention is biologically not a typical process where re-sistance processes are generated.
The advantages by a combination of artificial light together with water-soluble tetrapyrrole compounds according to the present invention versus state-of-the-art treatment of salmon lice relate to one or more of the following topics:
reduced amount of drugs, improved efficacy on salmon lice, reduced toxicity to the Atlantic salmon, resistance issues, cost and time.
Detailed description of the present invention Surprisingly it has been found a new method for treatment of salmon lice (L.
salmonis and C. rogercresseyi, Caligus spp.) in farmed fish such as Atlantic salmon (S.
salar L.) using an artificial light source and at least one chemical substance at toxicologically acceptable concentrations for Atlantic salmon.
The present invention relates to water-soluble tetrapyrrole compounds. More specifi-cally, the invention relates in a first aspect to a composition in the form of an aqueous solution comprising a tetrapyrrole for use in a method of therapy using artificial light for an external crustacean parasite infection in salmonid fish, said external crustacean parasite infection comprises an infection of salmon lice, Lepeophtheirus salmon/s1 Ca-ligus rogercresseyi and Caligus spp.
In one embodiment said water-soluble tetrapyrrole compound for use in a method of photodynamic therapy for an external crustacean parasite infection in salmonid fish is a water-soluble tetrapyrrole compound comprising one or more basic groups, such as aliphatic amino groups, or permanently charged nitrogen-comprising groups such as quaternary ammonium salts, one or more acidic groups such as sulfonic acid groups, phosphate groups or carboxylic groups, and/or one or more neutral hydrophilic groups like alcohols, phenols and/or polyethylene glycol.
The term "water-soluble tetrapyrrole compound" is herein any form of the tetrapyrrole compound on neutral or charged form. If the water-soluble tetrapyrrole compound is on charged form, the compound is in the form of a salt. Water-soluble tetrapyrrole salts are, according to the present invention any salt that is sufficient soluble in sea water, are toxic to salmon lice and are not toxic for fish including salmon with or with-out light. For tetrapyrroles with basic groups typical salts are formed with acids like hydrochloric acid, sulfuric acid, phosphoric acid, succinic acid and other typical non-5 toxic acids used in pharmaceuticals for veterinary or human use. For tetrapyrroles with acidic groups typical salts are formed with bases like sodium hydroxide, calcium hydroxide, magnesium hydroxide, amine salts and other typical non-toxic bases used in pharmaceuticals for veterinary or human use. The term "water-soluble tetrapyrrole compound" can also be the tetrapyrrole derivative (as salt or not as salt) in the form io of a complex with cyclodextrin.
The chemical group called cyclodextrin (CD) includes alpha-CD which is a 6-membered sugar ring molecule, beta-CD which is a 7-membered sugar ring molecule, gamma-CD
which is a 7-membered sugar ring molecule and an almost unlimited number of chem-ical derivatives with various degree of substitution on these three different sugar ring molecules.
Among the preferred water-soluble tetrapyrrole compounds according to the present invention are the corresponding cyclodextrin complexes. Regarding the cyclodextrin part of the water-soluble tetrapyrrole compound of cyclodextrin complexes are the following cyclodextrins preferred: unsubstituted cyclodextrin, methyl cyclodextrin and zo 2-hydroxypropyl cyclodextrin, and sulphobutyl-cyclodextrin. The most preferred cy-clodextrins have a 7-membered sugar ring molecular structure.
The term "water-soluble tetrapyrrole compound" also includes compounds where the tetrapyrrole ring system incorporates a metal ion.
Very many photoactive compounds described in the scientific literature are so-called "tetrapyrroles". This term relates to cyclic compounds comprising four 5-membered rings comprising a nitrogen atom. A typical tetrapyrrole core is porphyrin shown be-low.
\
-NH N-/
--N FINJ
Porphyrin The tetrapyrrole structures can be with various degrees of chemical double bonds as shown below forming different chemical ring structures. Chlorins and bacteriochlorins are reduced versions of porphyrin often referred to as hydroporphyrins.
Chlorins have one reduced double bond while bacteriochlorins have two reduced double bonds.
In phthalocyanines the four pyrrole ring structures are condensed with benzene rings.
The tetrapyrrole ring structure might optionally be condensed with other ring systems then benzene rings; for example a heterocyclic ring like pyridine.
/ ---- \ <,-.-,..--'''''."--=
NH N ' -NH N- ';----Nti N:=---',4,, / \ t ------N HN \ I \
\ . ',--r?4,<14-,..f.;.=
\ --...., --.......
Porphyrin Chlorin Bacteriochlorin <
:1 ,, -A His4----,i re , N
0 f Phthalocyanine The present invention relates to water-soluble tetrapyrrole compounds with or without additional ring systems. Methods for synthesis of water-soluble derivatives are well io described in the scientific literature and patent literature, e.g.
EP2464384. See for example Michael Luciano et al., 2017, Modifications of porphyrins and hydroporphyrins for their solubilization in aqueous media in Molecules: 22, 980, and references herein.
The abovementioned functional groups might be attached directly or indirectly to the tetrapyrrole ring or might be incorporated or attached to an additional ring system.
Talporfin is a substance in a drug (LaserphyrinC)) for treatment of lung cancer in hu-mans in Japan. Talporfin is a chlorin derivative. This is an example where three of four water-solubilizing groups, i.e. four acidic groups are indirectly bond to the tetrapyrrole derived ring system and one acidic group is directly bond.
HO
= 0 /N HN
N
Talporfin Tennoporfin is the substance in a drug (Foscan 10) for treatment of head and neck can-cer in humans. This is an example where the solubilizing phenolic groups are attached to an additional ring system. Phthalocyanines can also be modified to become water-soluble compounds by covalent attachment of water-solubilizing functional groups di-rectly or indirectly to additional rings.
N HO HN
) OH
Tennoporfin Some preferred water-soluble tetrapyrrole compounds to be used according to the present invention include:
= Tetrapyrrole compounds with carboxylate functional groups (typically 1 to carboxylic groups), except for chlorophyllin.
= Sulfonated tetrapyrrole compounds, typically with one to four sulphonic acid groups = Phosphate/phosphonate tetrapyrrole compounds, typically with one to six phosphate and/or phosphonate groups = 4-pyridinium-tetrapyrrole compounds, typically with one to four pyridinium groups = Other pyridyl-substituted tetrapyrrole compounds = Imidazolium-tetrapyrrole compounds = Tetrapyrrole compounds comprising alcohol, phenol, ether; typically PEGylated tetrapyrrole; typically with more than one oxygen-comprising functional group The above-mentioned compounds are preferably in the form of a pharmaceutically acceptable salt if the tetrapyrrole compound comprises one or more acidic and/or basic group. For a given tetrapyrrole salt, the stoichionnetric ratio between the ions might vary; for example, a tetrapyrrole phosphate ester might be in the form of monosodium salt or disodium salt.
The water-soluble tetrapyrrole compounds according to the present invention are easi-ly available:
= Several compounds are commercially available from different vendors.
= Very many compounds are described in the scientific literature and patent liter-ature with synthetic methods and chemical characterization methods and data.
= A person skilled in the art can utilize standard organic methods for preparation of compounds.
The present invention does not claim any new chemical compounds per se.
Salts of water-soluble tetrapyrrole compounds can easily be prepared by standard methods using an acidic compound and a basic compound. Such methods typically include mixing of relevant molecular ratios of acids and bases in an appropriate sol-vent, optionally heating and then isolation by evaporation or precipitation.
The water-soluble salt is dried using standard methods; air drying, head drying, vacuum drying and spray drying. The water-soluble tetrapyrrole cyclodextrin complexes according to the present invention can be prepared by standard methods for preparation of such complexes. These methods include co-evaporation, spray-drying, freeze drying and kneading. One simple method is to carefully mix the water-soluble tetrapyrrole with the cyclodextrin (typically molar ratio 1 to 5) with small amounts of water forming a very thick paste for 10 minutes using a mortar and pestle, dry the paste in an oven and prepare a powder of the dry material using the mortar and pestle.
The actual aqueous concentration of water-soluble tetrapyrrole compounds in the clini-cal situation to remove salmon lice from fish, varies depending upon the various pa-rameters like for example choice of water-soluble tetrapyrrole compound, tempera-ture, disease stage, light source and the density of Atlantic salmon. Typical concentration range for the water-soluble tetrapyrrole compound according to the pre-sent invention is in the range of 0.01 micromolar (10-8 M) to 400 micromolar (400 times 10-6 M). More preferred the concentration range for the water-soluble tetrapyrrole compounds according to the present invention is in the range 0.1 mi-cromolar to 200 micromolar.
The present invention relates to treatment of salmon louse in farmed fish populations that comprises a combination of water-soluble tetrapyrrole compounds and light from an artificial light source.
The present invention relates to a protocol for the present treatment.
Suitably, water-soluble tetrapyrrole compound(s) are administered prior to, after or at approximately the same time as the light.
The light might be present after the water-soluble tetrapyrrole compound concentra-tion around the Atlantic salmon is reduced. Any protocol using water-soluble tetrapyrrole and light is within the scope of the present invention. It is up to the io skilled person on salmon lice treatment to select the best suited protocol for each treatment.
A first preferred protocol is to apply the water-soluble tetrapyrrole some time prior to the light treatment. In this case the light and the water-soluble tetrapyrrole are pre-sent partly together and optionally continue to use light after the aqueous concentra-tion of the water-soluble tetrapyrrole is reduced.
A second preferred protocol is to apply water-soluble tetrapyrrole and artificial light treatment together and optionally continue to use light after the aqueous concentra-tion of the water-soluble tetrapyrrole is reduced.
A third preferred protocol is to apply light after the aqueous concentration of the wa-ter-soluble tetrapyrrole is reduced but the water-soluble tetrapyrrole still is present within the salmon lice.
The most preferred protocol is to apply light, at least partly, when the concentration of the water-soluble tetrapyrrole compounds still is quite high in the water surrounding the Atlantic salmon and the salmon lice.
The present invention relates to a protocol for the present treatment. The present treatment can be performed when the Atlantic salmon is in receptacles or enclosures, e.g. closed tanks or semi-closed tanks, pipes, chambers, containers, fishponds, ocean cages or net pens or a combination of such enclosures.
The preferred methods of the present invention relate to treatment of Atlantic salmon with salmon lice within a tank/boat or ocean cages or net pens. The absolutely most preferred methods of the present invention relate to treatment of Atlantic salmon in-fected with salmon lice within an ocean cage or a net pen.
The present invention relates to the position of the artificial light source.
One preferred position of the light source is in the air above the water. Another preferred position of the light source is on the walls or the bottom of a receptacle or enclosure, e.g. closed tank or semi-closed tank, pipe, chamber, container, or fishponds. Another preferred 5 position of the light source is under water within the receptacle or the ocean cage or net by mechanical arrangements and/or floating devices. The most preferred position of the light source in a large ocean cage or net is under water.
The artificial light source should generate light that has wave lengths from 200nm to 800nm. One preferred artificial light source according to the present invention is that io the artificial light source generates visible light within the wavelength band from 400nm to 800nm.
One preferred artificial light source according to the present invention is that the artifi-cial light source generates light within one of the following colors: red, yellow, green, or blue. The artificial light source may generate white light.
15 Another preferred light source according to the present invention is that the artificial light source generates UV light within the wavelength band from 200nm to 400nm.
Another preferred artificial light source according to the present invention is that the artificial light source generates UVC light within the wavelength band from 200nm to 300nm.
The artificial light source might also generate electromagnetic radiation that is outside these wavelength bands. If so, the artificial light source must also generate some light within referred wave lengths or colors.
The artificial light source can be one single artificial light source or a plurality of artifi-cial light sources. If the volume is huge, like in an ocean cage or net, it is according to the present invention preferred to use a plurality of artificial light sources.
One artificial preferred light source according to the present invention is that the artifi-cial light source is based on laser.
Another preferred artificial light source according to the present invention is that the artificial light source is based on LEDs, halogen lamp or mercury lamp. The most pre-ferred type of lamps among these lamps are LED lamps.
The most preferred artificial light sources according to the present invention are LED
lamps generating blue light; typically, in the wavelength range from 380nm to 500nm.
Examples of such lamps are optionally dimmable, underwater lamps currently com-mercially available and used in aquaculture for other purposes.
The light from the artificial light source may be stationary, i.e. same light in the same area over time, or the artificial light source may be movable.
The present invention relates to a drug treatment protocol. Optionally, according to the present invention, other drug substances or drug like compounds may, in addition to water-soluble tetrapyrrole, be useful for the treatment according to the present invention. One preferred treatment protocol according to the present invention is that the other drug substances or drug like compounds are selected among other drugs io that are regulatory approved for use to treat Atlantic salmon infected by salmon lice.
Another preferred treatment protocol according to the present invention is that the other drug substances or drug like compounds that are cholinesterase inhibitors, syn-thetic pyrethroids, chitin synthase inhibitors or glutamate-based chlorine ion channel regulators.
Another preferred treatment protocol according to the present invention is that the other drug substances or drug like compounds are selected among compounds that are water-soluble tetrapyrrole compounds. Another preferred treatment protocol ac-cording to the present invention is that the other drug substances or drug like com-pounds are selected among compounds that are phototoxic.
The present invention relates to the dose or concentration of the water-soluble tetrapyrrole in the clinical situation.
The present invention relates to the timing of the treatment process. The time neces-sary to perform the present process varies from minutes to hours depending upon several factors like for example nature of the salmon lice infection, number of Atlantic salmons per cubic meter, the nature and the concentration of the water-soluble tetrapyrrole and optionally other drugs and drug like compounds, and nature of the light source.
The present invention relates to resistance. The method according to the present in-vention is new for treatment of Atlantic salmon infected by salmon lice and has ad-vantages related to treatment of Atlantic salmon infected by resistant salmon lice and also relates to generation of new forms of resistance. The possible mechanism of ac-tion related to the present invention is biologically not a typical process where re-sistance processes are generated.
The present invention relates to compositions. The composition might be in the form of liquid concentrated solution or in the form of a solid powder. The concentrated solu-tion is diluted with sea water before use. The solid powder is typically dissolved to a concentrated solution and further diluted with sea water before use or optionally dis-solved directly in sea water. The solutions comprise one or more solvents. The sol-vents are selected among toxicologically acceptable solvents or solvent mixtures typi-cally for example selected from water, sea water, ethanol, isopropanol, glycerol, dimethyl sulfoxide, dimethyl fornnannide, acetone and low molecular weight polyeth-ylene glycols. The concentrate might typically comprise additional non-toxic additives io like surfactants and solubilizers used in pharmaceutical compositions for human and animal medical products. These additives include polysorbates like for example Poly-sorbate 20 and Polysorbate 80, polyoxyethylene (PEG) castor oil derivatives, polyox-anners, glycerol esters and other ionic and non-ionic surfactants and solubilizers. An-ionic surfactants are, according to the present invention, the most preferred group of ionic surfactants. However, the most preferred surfactants, according to the present invention, are non-ionic surfactants. Both ionic and non-ionic surfactants might work as solubilizers. The powder can be the water soluble tetrapyrrole active substance without any additives or a powder mixture comprising various additives. The additives to be optionally used in the present compositions include typical excipients used in pharmaceutical formulations like binders, carriers, coatings, diluents, disintegrants, stabilizers, surfactants, solubilizers and other typical pharmacologically inactive excipi-ents. Typical dry formulations are, according to the present invention, non-encapsulated dry powder (pure water-soluble tetrapyrrole derivatives or cyclodextrin derivatives thereof optionally mixed with additives), granulates comprising water-soluble tetrapyrrole derivatives or cyclodextrin derivatives thereof and dry powder or granulate comprising water-soluble tetrapyrrole derivatives or cyclodextrin derivatives thereof in water-soluble polymer bags, typically polyvinyl alcohol bags.
Granulates can typically be prepared using standard granulation methods for example well known in the field of tableting. For granulation methods see for example Dilip M.
Parikh (Ed.) Handbook of Pharmaceutical Granulation Technology, Second Edition (2005) Tay-lor&Francis Group, Florida, USA.
The advantages by a combination of light together with water-soluble tetrapyrrole de-fined in the present invention relate to one or more of the following topics:
reduced amount of drugs, reduction of environmental issues, no resistance development, im-proved efficacy on salmon lice, and reduced toxicity to the Atlantic salmon.
Experimental Example 1 Copper phthalocyanine-3,4',4",4m-tetrasulfonic acid tetrasodium salt - 2-hydroxypropyl-beta-cyclodextrin complex Copper phthalocyanine-3,4`,4",4"1-tetrasulfonic acid tetrasodium salt (Aldrich 5G SDS) (my 984.2, 492 mg, 0.5 mmol) and 2-hydroxypropyl-beta-cyclodextrin (Biosynth) (mw 1460, 3.65 g, 2.5 mmol) were mixed volumetrically in a mortar.
Wa-ter (2 ml) was added, and the blue paste was vigorously mixed in the mortar and then dried in an oven at 60 C for 24 hours. The content was pulverized in the mortar. The io title compound comprised 11.9 weight- k copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt.
Example 2 Copper phthalocyanine-3,4',4",4m-tetrasulfonic acid tetrasodium salt - beta-cyclodextrin sulfobutyl ether sodium salt complex Copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt (Aldrich 5G SDS) (my 984.2, 98 mg, 0.1 mmol) and beta-cyclodextrin sulfobutyl ether sodium salt (Biosynth 0C15979) (mw 2242, 2.24 g, 1 mmol) were mixed volumetrically in a mortar. Water (2 ml) was added, and the blue paste was vigorously mixed in the mor-tar and then dried in an oven at 60 C for 24 hours. The content was pulverized in the mortar. The title compound comprised 4.2 weight-% copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt.
Example 3 4,4',4",4"-(porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid) - be-ta-cyclodextrin sulfobutyl ether sodium salt complex 4,4',4",4"-(porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid) (Sigma-Aldrich)89456-100MG-F) (mw 935, 9 mg, 0.01 mmol) and beta-cyclodextrin sulfobutyl ether sodium salt (Biosynth 0C15979) (mw 2242, 0.22 g, 0.1 mmol) were mixed vol-umetrically in a mortar. Water (0.2 ml) was added, and the blue paste was vigorously mixed in the mortar and then dried in an oven at 60 C for 24 hours. The content was pulverized in the mortar. The title compound comprised 3.9 weight-% 4,4',4",4"-(porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid).
Example 4 Copper phthalocyanine-3,4',4",4--tetrasulfonic acid tetrasodium salt - gam-ma-cyclodextrin complex Copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt (Aldrich 5G SDS) (my 984.2, 492 mg, 0.5 mmol) and gamma-cyclodextrin (Wacker Fine Chemicals, Cavannax W8) (mw 1297, 2.40 g, 1.85 mmol) were mixed volumetrically in a mortar. Water (2 ml) was added, and the blue paste was vigorously mixed in the mortar and then dried in an oven at 60 C for 24 hours. The content was pulverized in the mortar. The title compound comprised 17 weight-% copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt.
Example 5 Copper phthalocyanine-3,4',4",4m-tetrasulfonic acid tetrasodium salt - beta-cyclodextrin complex Copper phthalocyanine-3,4',4",4"1-tetrasulfonic acid tetrasodium salt (Aldrich 5G SDS) (my 984.2, 492 mg, 0.5 mmol) and beta-cyclodextrin (Wacker Fine Chemi-cals, Cavamax W7 (mw 1135, 3,405g, 3 mmol) were mixed volumetrically in a mortar.
Water (2 ml) was added, and the blue paste was vigorously mixed in the mortar and then dried in an oven at 60 C for 24 hours. The content was pulverized in the mortar.
The title compound comprised 11.9 weight-% copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt.
Example 6 Phthalocyanine concentrate for dilution before use Copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt 500 gram Macrogol glycerol ricinolaeate 15 gram Polysorbate 80 10 gram N-nnethylpyrrolidon ad. 5 liter A stirred mixture of macrogol glycerol ricinolaeate, polysorbate 80 and N-methylpyrrolidone (3 liter) are heated to 60 'C. Copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt is added. Additional N-methylpyrrolidon to a total volume of 5 liter is added and the mixture was stirred for 10 minutes, cooled and filled on one-liter bottles. One liter comprises 100 gram copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt.
Example 7 Bag comprising dry powder of porphine - cyclodextrin complex 4,4',4",4"'-(porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid) - beta-cyclodextrin sulfobutyl ether sodium salt complex 100 gram 5 Kaolin 350 gram Silica 50 gram The components are volumetrically mixed and filled into polymer bags made from polvinylalcohol. Each bag comprises 100 gram dry powder (20 gram 4,4',4",4"-(porphine-5,10,15,20-tetrayl)tetrakis(benzenesulfonic acid) - beta-cyclodextrin sul-
10 fobutyl ether sodium salt complex.) Example 8 Solubility and dispersibility studies in sea water Copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodium salt. Visual solubility in sea water appr. 20 mg/liter at 20 C. Dissolves over time. Blue solution.
15 The tetrapyrrole cyclodextrin complexes showed typically a visual solubility in sea wa-ter more than appr. 100 mg/liter at 20 C. The tetrapyrrole cyclodextrin complexes typically dissolve fast in sea water and are typically very dispersible in sea water.
Example 9 Evaluation of clinical efficacy of positively charged porphyrin to kill salmon 20 lice (dark and blue light) Drug: 5,10,15,20-tetrakis(1-nnethy1-4-pyridinio)porphyrin tetra(p-toluenesulfonate) 20 nnicroM Molecular weight is 1363.60 D.
(Synonym: nneso-tetra(N-methyl-4-pyridyl)porphine tetratosylate salt; TMPyP) from Merck (Sigma Aldrich) 323497-250MG
Blue light: 100 blue LED lamp array (10 x 10) is mounted on a heat sink and cooled by an external fan. Specifications: 450-460nm, DC32-36V, 3500mA (100W), Lumi-nous flux: 1000-1500Im.
Two dark controls (A and B): Sea water (A); and drug (20 microM) in sea water (B) Blue light control: Sea water no drug (C) Blue light: Drug (20 nnicroM) in sea water (D).
All bioassays are conducted at a constant water temperature of 12 C. Numbers of live and dead salmon lice were evaluated during four hours after onset of experiments.
Expected result: No dead salmon lice are observed in controls (A, B and C).
Dead salmon lice are observed in experiment with blue light and water-soluble tetrapyrrole compound (D).
Example 10 Evaluation of clinical efficacy of negatively charged porphyrin to kill salmon lice (dark and blue light) Drug: 4,4',4",4--(porphine-5,10,15,20-tetrayptetrakis(benzenesulfonic acid) (Synonym: nneso-tetraphenylporphine-4,4',4",4--tetrasulfonic acid) from Merck (Sigma Aldrich) 89456-100MG
Two dark controls (A and B): Sea water (A) and drug (10 microM) in sea water (B) Blue light control: Sea water no drug (C) Blue light: Drug (10 microM) in sea water (D).
All bioassays are conducted at a constant water temperature of 12 C. Numbers of live and dead salmon lice were evaluated during four hours after onset of experiments.
Expected result: No dead salmon lice are observed in controls (A, B and C).
Dead salmon lice are observed in experiment with blue light and water-soluble tetrapyrrole compound (D).
Example 11 Evaluation of clinical efficacy of positively charged porphyrin to kill salmon lice (dark, white light and blue light) Drug: Copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodiunn salt from Merck (Sigma Aldrich) 245356-1G
Two dark controls (A and B): Sea water (A) and drug (10 microM) in sea water (B) Blue light control: Sea water no drug (C) White light control: Sea water no drug (D) Blue light: Drug (10 microM) in sea water (E).
White light: Drug (10 microM) in sea water (F).
All bioassays are conducted at a constant water temperature of 12 C. Numbers of live and dead salmon lice were evaluated during four hours after onset of experiments.
Expected result: No dead salmon lice are observed in controls (A, B, C and D).
Dead salmon lice are observed in experiments with light and water-soluble tetrapyrrole compound. More and/or faster killing of salmon lice is observed with blue light plus water-soluble tetrapyrrole compound (E) than with white light plus water-soluble tetrapyrrole compound (F).
15 The tetrapyrrole cyclodextrin complexes showed typically a visual solubility in sea wa-ter more than appr. 100 mg/liter at 20 C. The tetrapyrrole cyclodextrin complexes typically dissolve fast in sea water and are typically very dispersible in sea water.
Example 9 Evaluation of clinical efficacy of positively charged porphyrin to kill salmon 20 lice (dark and blue light) Drug: 5,10,15,20-tetrakis(1-nnethy1-4-pyridinio)porphyrin tetra(p-toluenesulfonate) 20 nnicroM Molecular weight is 1363.60 D.
(Synonym: nneso-tetra(N-methyl-4-pyridyl)porphine tetratosylate salt; TMPyP) from Merck (Sigma Aldrich) 323497-250MG
Blue light: 100 blue LED lamp array (10 x 10) is mounted on a heat sink and cooled by an external fan. Specifications: 450-460nm, DC32-36V, 3500mA (100W), Lumi-nous flux: 1000-1500Im.
Two dark controls (A and B): Sea water (A); and drug (20 microM) in sea water (B) Blue light control: Sea water no drug (C) Blue light: Drug (20 nnicroM) in sea water (D).
All bioassays are conducted at a constant water temperature of 12 C. Numbers of live and dead salmon lice were evaluated during four hours after onset of experiments.
Expected result: No dead salmon lice are observed in controls (A, B and C).
Dead salmon lice are observed in experiment with blue light and water-soluble tetrapyrrole compound (D).
Example 10 Evaluation of clinical efficacy of negatively charged porphyrin to kill salmon lice (dark and blue light) Drug: 4,4',4",4--(porphine-5,10,15,20-tetrayptetrakis(benzenesulfonic acid) (Synonym: nneso-tetraphenylporphine-4,4',4",4--tetrasulfonic acid) from Merck (Sigma Aldrich) 89456-100MG
Two dark controls (A and B): Sea water (A) and drug (10 microM) in sea water (B) Blue light control: Sea water no drug (C) Blue light: Drug (10 microM) in sea water (D).
All bioassays are conducted at a constant water temperature of 12 C. Numbers of live and dead salmon lice were evaluated during four hours after onset of experiments.
Expected result: No dead salmon lice are observed in controls (A, B and C).
Dead salmon lice are observed in experiment with blue light and water-soluble tetrapyrrole compound (D).
Example 11 Evaluation of clinical efficacy of positively charged porphyrin to kill salmon lice (dark, white light and blue light) Drug: Copper phthalocyanine-3,4',4",4"-tetrasulfonic acid tetrasodiunn salt from Merck (Sigma Aldrich) 245356-1G
Two dark controls (A and B): Sea water (A) and drug (10 microM) in sea water (B) Blue light control: Sea water no drug (C) White light control: Sea water no drug (D) Blue light: Drug (10 microM) in sea water (E).
White light: Drug (10 microM) in sea water (F).
All bioassays are conducted at a constant water temperature of 12 C. Numbers of live and dead salmon lice were evaluated during four hours after onset of experiments.
Expected result: No dead salmon lice are observed in controls (A, B, C and D).
Dead salmon lice are observed in experiments with light and water-soluble tetrapyrrole compound. More and/or faster killing of salmon lice is observed with blue light plus water-soluble tetrapyrrole compound (E) than with white light plus water-soluble tetrapyrrole compound (F).
Claims (7)
1. Composition in the form of an aqueous solution comprising a chemical com-pound for use in a method of therapy using artificial light for an external crus-tacean parasite infection in salmonid fish, said external crustacean parasite infection comprises an infection of salmon lice, Lepeophtheirus salmonis, Ca-ligus rogercresseyi and Caligus spp., wherein said chemical compound is a water-soluble tetrapyrrole compound or a pharmaceutical acceptable deriva-tive thereof, with the proviso that the water-soluble tetrapyrrole is not chloro-phyllin.
2. A composition according to claim 1, where said water-soluble tetrapyrrole compound is a member of a group of porphyrins, or an acceptable pharma-ceutical derivative thereof.
3. A composition according to claim 1, where said water-soluble tetrapyrrole compound is a member of a group of chlorins, or an acceptable pharmaceuti-cal derivative thereof.
4. A composition according to claim 1, where said water-soluble tetrapyrrole compound is a member of a group of bacteriochlorins, or an acceptable phar-maceutical derivative thereof.
5. A composition according to claim 1, where said water-soluble tetrapyrrole compound is a member of a group of phthalocyanines, or an acceptable pharmaceutical derivative thereof.
6. A composition according to any one of claim 1 to 5, where said water-soluble tetrapyrrole compound is in a form of a toxicologically acceptable salt.
7. A composition according to any one of claim 1 to 6, where said water-soluble tetrapyrrole compound is in a form of a toxicologically acceptable cyclodextrin complex.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20200710 | 2020-06-17 | ||
| NO20200710 | 2020-06-17 | ||
| PCT/NO2021/050146 WO2021256938A1 (en) | 2020-06-17 | 2021-06-16 | Method for removing crustacean ectoparasites from farmed salmonid fish using water-soluble tetrapyrrole compounds and light |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3181123A1 true CA3181123A1 (en) | 2021-12-23 |
Family
ID=79268177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3181123A Pending CA3181123A1 (en) | 2020-06-17 | 2021-06-16 | Method for removing crustacean ectoparasites from farmed salmonid fish using water-soluble tetrapyrrole compounds and light |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4167729A4 (en) |
| CA (1) | CA3181123A1 (en) |
| CL (1) | CL2022003628A1 (en) |
| DK (1) | DK202270639A1 (en) |
| NO (1) | NO347612B1 (en) |
| WO (1) | WO2021256938A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19910561A1 (en) * | 1999-03-10 | 2000-09-14 | Schaffer Moshe | Use of porphyrin derivatives in aquariums |
| US8859760B2 (en) * | 2008-07-29 | 2014-10-14 | Frontier Scientific, Inc. | Compositions for killing or preventing the growth of microbes |
| EP2317857B1 (en) * | 2008-07-29 | 2016-12-28 | Frontier Scientific, Inc. | Use of tetrakis(n-alkylpyridinium)-porphyrin derivatives for killing microbes or preventing their growth |
| NO346510B1 (en) * | 2018-12-17 | 2022-09-12 | Mowi ASA | Method for removing crustacean ectoparasites from farmed salmonid fish using edible additives and light |
-
2021
- 2021-06-16 EP EP21825236.9A patent/EP4167729A4/en active Pending
- 2021-06-16 NO NO20210775A patent/NO347612B1/en unknown
- 2021-06-16 DK DKPA202270639 patent/DK202270639A1/en unknown
- 2021-06-16 WO PCT/NO2021/050146 patent/WO2021256938A1/en active Application Filing
- 2021-06-16 CA CA3181123A patent/CA3181123A1/en active Pending
-
2022
- 2022-12-16 CL CL2022003628A patent/CL2022003628A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021256938A1 (en) | 2021-12-23 |
| NO347612B1 (en) | 2024-01-29 |
| EP4167729A1 (en) | 2023-04-26 |
| NO20210775A1 (en) | 2021-12-20 |
| DK202270639A1 (en) | 2023-01-06 |
| CL2022003628A1 (en) | 2023-06-23 |
| EP4167729A4 (en) | 2024-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Amor et al. | Sunlight-activated insecticides: historical background and mechanisms of phototoxic activity | |
| Anas et al. | Advances in photodynamic antimicrobial chemotherapy | |
| F Sperandio et al. | Antimicrobial photodynamic therapy to kill Gram-negative bacteria | |
| Alves et al. | Potential applications of porphyrins in photodynamic inactivation beyond the medical scope | |
| Hamblin et al. | Photodynamic inactivation of microbial pathogens: medical and environmental applications | |
| Rosa et al. | Antimicrobial photodynamic therapy: a new therapeutic option to combat infections | |
| US20100266716A1 (en) | Natural Photodynamic Agents and their use | |
| ES2778844T3 (en) | Complemented fish feed | |
| DK202170358A1 (en) | Composition for removing crustacean ectoparasites from farmed salmonid fish using curcumin or a pharmaceutical acceptable derivate thereof and light | |
| Jori et al. | Photodynamic inactivation of microbial pathogens: disinfection of water and prevention of water-borne diseases | |
| ITRM20100524A1 (en) | COMPOSITION INCLUDING A LARVICID PHOTOACTIVABLE | |
| Magaraggia et al. | Porphyrin-silica microparticle conjugates as an efficient tool for the photosensitised disinfection of water contaminated by bacterial pathogens | |
| CN106620695B (en) | Photosensitive medicinal preparation for photodynamic sterilization and application thereof | |
| Brovko | Photodynamic treatment: a new efficient alternative for surface sanitation | |
| CA3181123A1 (en) | Method for removing crustacean ectoparasites from farmed salmonid fish using water-soluble tetrapyrrole compounds and light | |
| RU2646477C1 (en) | Photosensitiser for treatment of cancer diseases and method of its obtaining | |
| KR101800810B1 (en) | Method for prevention and treatment for scuticociliatosis in fishes using blue light emitting diode(LED) | |
| RU2152790C1 (en) | Agent for photodynamic diagnosis and therapy of oncological diseases | |
| KR100811110B1 (en) | Feed additive containing alpha-lipoic acid capsule composition stabilized in water phase for increasing immunity of fish and method for using the same | |
| FR2584927A1 (en) | LIQUID, STABLE, ANTHELMINTHIC AND FUNGICIDE COMPOSITION BASED ON BITHIONOL SULFOXIDE | |
| Magaraggia et al. | Photodynamic approaches to water disinfection | |
| Phoenix et al. | Light activated compounds as antimicrobial agents-patently obvious? | |
| Barber et al. | Photosensitizing activities of picket fence porphyrins in vitro and in vivo | |
| US20160008468A1 (en) | Disease detection and treatment through activation of compounds using external energy | |
| Ganga | Natural Photosensitisers for Antimicrobial Therapy |